GlobeNewswire Clinical StudiesOriginal article
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study
Data ReadoutpositivePositive
AI Analysis
Summary
Nexalin Technology announces secondary analysis of previously published clinical trial data showing improvements in memory, comprehension, and language function in Alzheimer's patients, with findings intended to guide design of a planned U.S. Alzheimer's pilot study.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Secondary analysis of ADAS-Cog subscale data reveals previously unreported improvements in memory, comprehension and language function in Alzheimer's patients
Importance:5/10
Sentiment:
0.70
Alzheimer's diseasecognitive functionADAS-Cogsecondary analysispilot study planned
Read the original article
Published by GlobeNewswire Clinical Studies on September 3, 2026 12:30 PM